Premium
NewAmsterdam Pharma Company NV (NAMS)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-26 | Ms. Louise KooijCAO | -65,00k | 1,67M | Derivative Exercise and Sale | 10,00 - 35,69 | 2,35k | - |
| 2026-05-08 | Bain Capital Life Sciences Investors, LLCSociété | -3,50M | 131,55M | Vente | 37,22 - 39,98 | 2,17M | -61,69% |
| 2026-03-11 | Dr. Louis G. LangeIndependent Non-Executive Director | -44,62k | 1,36M | Vente | 30,41 - 31,23 | 2,32k | -95,06% |
| 2026-03-09 | Dr. Louis G. LangeIndependent Non-Executive Director | 44,62k | 513,12k | Derivative Exercise and Retained Stock | 11,50 | 46,94k | 1 923,23% |
| 2026-03-06 | Dr. Louis G. LangeIndependent Non-Executive Director | -28,19k | 828,95k | Vente | 29,41 | 46,94k | -37,52% |
| 2026-03-05 | Dr. Johannes Jacob Pieter KasteleinFounder, Chief Scientific Officer, Member of Executive Board & Director | -300,00k | 9,09M | Derivative Exercise and Sale | 30,29 - 30,32 | 74,64k | - |
| 2026-03-02 | Dr. Michael Harvey DavidsonCEO, President & Executive Director | -443,71k | 14,75M | Derivative Exercise and Sale | 33,25 | 296,51k | - |
| 2026-02-24 | Dr. Michael Harvey DavidsonCEO, President & Executive Director | -306,29k | 10,58M | Derivative Exercise and Sale | 33,63 - 36,68 | 296,51k | - |
| 2026-02-20 | Dr. Johannes Jacob Pieter KasteleinFounder, Chief Scientific Officer, Member of Executive Board & Director | -45,48k | 1,61M | Vente | 35,00 - 35,46 | 74,64k | -37,86% |
| 2026-01-27 | Ms. Louise KooijCAO | -72,43k | 1,55M | Derivative Exercise and Sale | 10,90 - 32,62 | 2,35k | - |
| 2026-01-23 | Ms. Louise KooijCAO | -72,57k | 1,62M | Derivative Exercise and Sale | 10,90 - 34,37 | 2,35k | - |
| 2026-01-20 | Mr. Mayur Amrat SomaiyaCFO | -100,00k | 2,33M | Derivative Exercise and Sale | 9,26 - 33,80 | 7,55k | - |
| 2026-01-07 | Dr. Michael Harvey DavidsonCEO, President & Executive Director | -11,58k | 0,00 | Vente | - | 296,51k | -3,76% |
| 2026-01-05 | Dr. Johannes Jacob Pieter KasteleinFounder, Chief Scientific Officer, Member of Executive Board & Director | -6,00k | 199,50k | Vente | 33,25 | 120,12k | -4,76% |
| 2026-01-05 | Ms. Louise KooijCAO | -2,65k | 88,01k | Vente | 33,25 | 2,35k | -52,94% |
| 2026-01-05 | Mr. Mayur Amrat SomaiyaCFO | -5,12k | 170,17k | Vente | 33,25 | 7,55k | -40,40% |
| 2025-12-23 | Ms. Louise KooijCAO | -145,00k | 3,74M | Derivative Exercise and Sale | 10,00 - 36,21 | 15,00k | - |
| 2025-02-12 | Bain Capital Life Sciences Investors, LLCSociété | -4,80M | 168,48M | Vente | 35,10 | 297,56k | -94,16% |
| 2025-09-17 | Frazier Life Sciences Management, LPSociété | 21,46k | 508,55k | Achat | 23,70 | 12,90M | 0,17% |
| 2025-09-17 | Frazier Life Sciences Public Overage Fund, L.P.Société | 4,71k | 111,70k | Achat | 23,70 | 0,00 | -100,00% |
| 2025-11-01 | Frazier Life Sciences Public Overage Fund, L.P.Société | -2,99M | 0,00 | Vente | - | 0,00 | -100,00% |
| 2025-11-01 | Frazier Life Sciences Management, LPSociété | 2,99M | 0,00 | Achat | - | 12,90M | 30,16% |
| 2025-09-15 | Frazier Life Sciences Management, LPSociété | 660,00 | 15,64k | Achat | 23,70 | 13,65M | 0,00% |
| 2025-09-09 | Ms. Louise KooijCAO | -150,00k | 2,37M | Derivative Exercise and Sale | 10,00 - 26,11 | 15,00k | - |
| 2025-09-08 | Frazier Life Sciences Management, LPSociété | 1,26k | 31,49k | Achat | 24,99 | 13,65M | 0,01% |
| 2025-09-03 | Ms. Louise KooijCAO | -18,07k | 453,45k | Vente | 25,09 | 0,00 | -100,00% |
| 2025-09-02 | Ms. Louise KooijCAO | 18,07k | 0,00 | Derivative Exercise and Retained Stock | - | 33,07k | 120,49% |
| 2025-08-25 | Ms. Louise KooijCAO | -8,27k | 205,57k | Vente | 24,86 | 0,00 | -100,00% |
| 2025-08-21 | Dr. Johannes Jacob Pieter KasteleinFounder, Chief Scientific Officer, Member of Executive Board & Director | -100,00k | 2,47M | Vente | 24,29 - 25,49 | 114,78k | -46,56% |
| 2025-08-11 | Frazier Life Sciences Management, LPSociété | 2,19k | 52,54k | Achat | 23,98 | 59,65k | 3,81% |
| 2025-08-11 | Frazier Life Sciences Management, LPSociété | 471,00 | 11,29k | Achat | 23,98 | 9,85M | 0,00% |
| 2025-08-08 | Forbion Capital Partners B.V.Société | -53,31k | 1,35M | Vente | 25,00 - 25,28 | 5,93M | -0,89% |
| 2025-07-15 | Mr. Douglas F. KlingCOO | -98,61k | 1,02M | Derivative Exercise and Sale | 10,90 - 22,12 | 0,00 | - |
| 2025-06-24 | Frazier Life Sciences Management, LPSociété | 3,78k | 69,47k | Achat | 18,26 - 18,43 | 9,29M | 0,04% |
| 2025-06-16 | Mr. Douglas F. KlingCOO | -100,00k | 909,43k | Derivative Exercise and Sale | 10,00 - 19,75 | 0,00 | - |
| 2025-06-16 | Frazier Life Sciences Management, LPSociété | 8,58k | 167,38k | Achat | 19,50 | 9,29M | 0,09% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
